What is the Difference Between Compounded Semaglutide and Wegovy?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide—the active ingredient in both Wegovy and compounded formulations—activates GLP-1 receptors that regulate appetite and blood sugar. While Wegovy is a brand-name injectable medication, compounded semaglutide offers an alternative pathway to access the same therapeutic compound at a different price point and with greater flexibility in dosing schedules.

What Is Compounded Semaglutide?

Compounded semaglutide is semaglutide prepared in a licensed 503A compounding pharmacy according to a physician's prescription. The pharmacy sources pharmaceutical-grade semaglutide and combines it with sterile diluents and stabilizers to create injectable or oral formulations tailored to individual patient needs. This customization allows prescribers to adjust concentrations and volumes based on a patient's response, medical history, and metabolic profile.

PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies, which operate under strict FDA oversight and state pharmacy board regulations. These facilities follow USP <797> standards for sterile compounding and must verify the purity, potency, and safety of all ingredients before dispensing. The compounding process takes 5–7 business days, ensuring each dose is prepared fresh for the patient.

How Wegovy Differs From Compounded Semaglutide

Wegovy is a pre-filled injectable pen manufactured by Novo Nordisk under FDA approval as a branded pharmaceutical. It contains semaglutide at fixed concentrations (0.25, 0.5, 1.0, and 2.4 mg per dose) in a proprietary formulation designed for once-weekly subcutaneous injection. Patients must follow Novo Nordisk's titration schedule, which typically advances from 0.25 mg weekly and increases every four weeks until reaching the target maintenance dose.

Compounded semaglutide offers flexibility that Wegovy cannot match. Prescribers can recommend customized dose intervals, split doses, or adjusted concentrations if a patient experiences side effects or plateaus in weight loss response. PlexusDx pricing remains flat at $149 per month regardless of dose strength—meaning your dose may increase, but your price won't. Wegovy pricing is typically higher and tied to the specific pen strength, often ranging $900–$1,400 monthly before insurance coverage.

Efficacy and Clinical Evidence

Both compounded and brand-name semaglutide contain identical active pharmaceutical ingredient, so clinical outcomes at matched doses are expected to be equivalent. The landmark STEP trials that demonstrated Wegovy's efficacy (13.6% average body weight reduction over 68 weeks) are based on semaglutide itself, not Wegovy's specific formulation. Patients using compounded semaglutide at the same doses should achieve comparable results when adherence, diet, and lifestyle are consistent.

Response variability between individuals often depends on genetic factors that influence GLP-1 receptor sensitivity and peptide metabolism. PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 49 peptides—including GLP1R rs6923761 and GIPR rs1800437—to predict individual semaglutide response potential. This genetic insight can help optimize dosing strategy and inform whether compounded semaglutide or dual-compound options (like GLP-Squared) may offer better outcomes.

Cost, Access, and Insurance Coverage

PlexusDx compounded semaglutide injections start at $149 per month and serve all 50 states without requiring insurance, membership fees, or prior authorization. The flat monthly pricing model eliminates uncertainty—whether a patient is on 0.5 mg or 2.4 mg weekly, the monthly cost remains the same. HSA and FSA accounts are eligible for PlexusDx medications, allowing tax-advantaged spending on compounded therapy.

Wegovy typically costs $900–$1,400 monthly before insurance, and many plans classify it as a weight-loss medication (not medically necessary), resulting in high out-of-pocket costs or coverage denial. Compounded semaglutide through PlexusDx removes this barrier: no insurance pre-authorization delays, no deductibles, and direct transparent pricing. For patients seeking affordability and rapid access, compounded semaglutide offers a practical alternative that doesn't compromise on pharmaceutical standards or clinical outcomes.

Safety, Quality, and Regulatory Standards

Compounded semaglutide prepared by 503A pharmacies must meet the same purity and sterility standards as FDA-approved medications. Each batch undergoes microbial and endotoxin testing before release, and pharmacy compounders are subject to surprise FDA inspections and state-level audits. PlexusDx partners exclusively with 503A pharmacies that maintain comprehensive quality assurance protocols and traceability documentation for every compound.

While compounded medications are not FDA-approved (because they are individually prepared, not mass-manufactured), they operate under a robust legal framework and clinical supervision. The FDA recognizes compounding as an essential service for patients who cannot tolerate commercial formulations or require dose customization. Side effect profiles, injection site reactions, and systemic safety for compounded semaglutide are identical to Wegovy because the active ingredient is chemically identical—differences in tolerability typically reflect individual patient variation, not formulation quality.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as Wegovy?

Yes. Both contain identical semaglutide at matched doses, so efficacy is equivalent. Clinical trial evidence for semaglutide's 13–14% average weight loss applies to the active ingredient itself, not Wegovy's specific brand. Response depends on genetics, adherence, and lifestyle—not the manufacturer.

Why is compounded semaglutide cheaper than Wegovy?

Compounded medications bypass brand-name manufacturing, marketing, and distribution costs. PlexusDx sources from licensed 503A pharmacies at bulk pharmaceutical rates and passes savings directly to patients. At $149/month, compounded semaglutide costs roughly 85–90% less than Wegovy without sacrificing pharmaceutical standards.

Can I switch between compounded and brand-name semaglutide?

Yes. Both are semaglutide, so switching is straightforward with prescriber approval. Some patients alternate during shortages or adjust based on preference—Wegovy's fixed pens versus PlexusDx's flexible dosing. Your prescriber can coordinate the transition to ensure continuity of therapy.

Is compounded semaglutide FDA-approved?

Compounded medications are not FDA-approved as individual products because they are prepared per-patient prescription, not mass-manufactured. However, 503A compounding pharmacies operate under strict FDA oversight and state licensing. The semaglutide raw ingredient meets the same pharmacopeial standards as Wegovy's ingredient.

How can genetic testing help me choose between semaglutide options?

PlexusDx's Precision Peptide Genetic Test analyzes GLP1R and GIPR variants that influence semaglutide sensitivity and response speed. Results guide whether standard semaglutide dosing fits your profile or whether a dual-compound option like GLP-Squared may optimize results. Testing is available for $99 after your first month of treatment.

Does PlexusDx require insurance to prescribe compounded semaglutide?

No. PlexusDx serves all 50 states without insurance requirements, membership fees, or prior authorization. HSA and FSA accounts are eligible. Direct pricing at $149/month makes compounded semaglutide accessible regardless of insurance status.

Related Reading

• Compounded Semaglutide 2
• Compounded Semaglutide
• Difference Between Age Related Memory Loss And Dementia
• What S The Difference Between A Food Allergy And A Food Sensitivity

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.